Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19
ChromaDex recently published the results from a Phase 2 study on the preprint server medRXiv of their finding that addition of the NR nutritional protocol CMCS into COVID-19 pathway reducing recovery time from 9.3 days in mild to moderate patients to 6.6 days which represents a 29% reduction when receiving the standard of care in combination with nicotinamide riboside designed to promote healthy mitochondrial function.
100 Mild to moderate COVID-19 patients in this open-label, placebo-controlled Phase 2 study received at random the nutritional protocol on a 3:1 basis consisting of (CMCS) nicotinamide riboside, N-acetyl-L-cysteine, L-carnitine tartrate, and L-serine or placebo in combination with hydroxychloroquine which is the standard of care in Turkey. In addition to reduced recovery time, the patients experienced significant improvements in liver function with significant reductions in plasma ALT, AST, and LDH levels.
“This clinical study on nearly 100 subjects resulted in significantly speedier recovery time for COVID-19 patients and builds upon the existing research,” said ChromaDex Chief Executive Officer Rob Fried. “There are currently 11 published human clinical studies showing the safety and efficacy of NR in various indications and several dozen more in the works including studies specifically focused on COVID-19.”
“Given the scientific understanding that people with various metabolic conditions have a greater risk of poor outcomes following a COVID-19 diagnosis, it is important to understand the potential benefit of mitochondrial health in aiding patient recovery,” said Dr. Mardinoglu. “The insights provided by this data warrant further clinical study of this nutrient protocol in combination with standard of care to reduce recovery time from COVID-19. We look forward to the initiation of a Phase 3 study in the near future.”
“This is a positive and timely clinical trial with a powerful topline result showing accelerated recovery of Turkish COVID-19 patients treated with a nutrient protocol including 2 grams of daily NR,” said Dr. Brenner. “The findings of this study are consistent with the results of previous preclinical research in which we’ve seen beneficial effects on circulating liver enzymes, anti-inflammatory effects, and boosted innate antiviral immune defenses.”
Based on their findings the researchers concluded that “In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo. We observed that CMSC is associated with a low incidence of adverse events.”
